Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine

Kavita Panwar, Anna Godi, Clementina E. Cocuzza, Nick Andrews, Jo Southern, Paul Turner, Elizabeth Miller, Simon Beddows*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.

Original languageEnglish
Pages (from-to)1198-1202
Number of pages5
JournalVaccine
Volume40
Issue number9
Early online date1 Feb 2022
DOIs
Publication statusPublished - 23 Feb 2022

Bibliographical note

Funding Information: This work was supported by the UK Health Security Agency. This publication is independent research part funded by the National Institute for Health Research Policy Research Programme (“Vaccine Evaluation Consortium Phase II”, 039/0031). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Open Access: No Open Access licence.

Publisher Copyright: Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.

Citation: Panwar, Kavita, et al. "Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine." Vaccine (2022).

DOI: https://doi.org/10.1016/j.vaccine.2022.01.041

Keywords

  • Antibody
  • Durability
  • Human papillomavirus
  • Vaccine

Fingerprint

Dive into the research topics of 'Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine'. Together they form a unique fingerprint.

Cite this